PT-141 peptide.

What is PT-141 peptide?

PT-141 is bremelanotide, a peptide studied for increasing sexual desire and improving arousal. Its best-established benefit is improved desire and less distress about low desire in premenopausal women with acquired, generalized hypoactive sexual desire disorder, or HSDD. “Acquired” means desire declined after a period without that problem; “generalized” means the difficulty occurs across situations. [1]

The approved injectable medicine, Vyleesi, uses 1.75 mg at least 45 minutes before anticipated sexual activity. It comes in a single-use autoinjector. The supplied 10 mg powder vial and nasal spray are research-labelled products with different preparation and testing information; the clinical results belong to the studied medicine and route.

PT-141 acts at melanocortin receptors involved in signalling within the brain. It is a seven-amino-acid cyclic peptide. The exact mechanism that improves HSDD symptoms has not been established, even though its receptor activity is known. This matters because “brain-acting” does not mean a predictable switch that makes every person feel desire after every dose. [1]

PT-141 benefits: desire, arousal and less distress

Increased desire means greater interest or motivation; arousal is the body's response. They can change differently. A person may want sex but struggle with an erection, or have a physical response without wanting sex. PT-141 searches often combine these concerns, although the largest trials specifically enrolled women whose low desire was distressing. [2]

The trial findings do not establish a guaranteed orgasm, longer intercourse or a fixed improvement in erection hardness. They also do not show that everyone with a temporarily lower sex drive needs treatment. The clinical benefit is tied to the symptom and population actually studied.

The PT-141 benefits article covers the measured changes in desire, arousal and distress, with the evidence for women and men kept distinct.

What results can someone expect?

About 58% of women receiving bremelanotide reported a meaningful perceived benefit in the two main trials, compared with about 35–36% receiving placebo. The exact comparisons were 58.3% versus 36.1%, and 58.2% versus 35.4%. This was a questionnaire assessment across treatment, not a success rate for a single injection or a percentage increase in libido. [2]

Desire scale: 1.2–6, with higher scores indicating more desire. Distress scale: 0–4, with lower scores indicating less bother. These are mean changes at the last study visit; participants who completed treatment were assessed at week 24. [1]

For example, the first active-treatment group began at a mean desire score of 2.1 and improved by 0.5 points. Adding those rounded figures gives approximately 2.6. That calculation describes a group average; it cannot predict an individual's sensation after their first administration.

The trials did not show a significant increase in the number of satisfying sexual events compared with placebo. Greater desire and less distress were the clearest findings. The before-and-after article shows the score changes, responder percentages and timing together, including outcomes that did not improve. [2]

PT-141 dosage: amount, frequency and timing

The approved Vyleesi dose is 1.75 mg by subcutaneous injection, at least 45 minutes before anticipated sexual activity. This regimen applies to eligible premenopausal women with HSDD. It is not weight-based. The label allows no more than one administration in 24 hours and advises against more than eight in a month. [1]

If an administration occurred at 10 pm, 8 am the next morning is only ten hours later. The 24-hour limit still applies. Similarly, eight monthly administrations are a ceiling in the labelled regimen, not a target that needs to be reached.

There is no approved PT-141 dosing schedule for men. Historical injected and nasal amounts were studied under different protocols and cannot be combined into a single universal schedule. A nasal amount also cannot be substituted milligram-for-milligram for the injection. The dosage and timing page gives the attributable research amounts, applicable injection sites and the calculation details.

How many syringe units is 1.75 mg?

With 10 mg in a final volume of 2 mL, 1.75 mg equals 0.35 mL, or 35 units on a U-100 syringe. This is a concentration example. The supplied vial does not come with a verified medicinal preparation recipe, and the example does not establish that its powder is interchangeable with the approved autoinjector.

Then 1.75 ÷ 5 = 0.35 mL. Since 100 U-100 units occupy 1 mL, the calculated draw is 35 units. Changing the final volume changes the syringe number: at 1 mL total, the same 1.75 mg occupies 0.175 mL, or 17.5 units.

The product contains 10 mg in total. Ten milligrams is not the amount to use at once, and a 3 mL vial describes the container capacity rather than a supplied liquid volume. The PT-141 calculator accepts the vial amount, final solution volume and target in mg or mcg, then displays the volume and moving syringe marker.

How long does PT-141 take to work?

At least 45 minutes is the approved lead time; a precise duration of benefit after each dose has not been established. The prescribing information does not promise a 24-, 36- or 72-hour effect. It also says the optimal administration window is not fully characterized. Individual timing has to account for both perceived benefit and unwanted effects such as nausea. [1]

Two time scales matter. The medicine is administered around anticipated activity, while trial questionnaires assess changes in desire and distress over several weeks. Improvements were detectable at the first scheduled assessment at week four and persisted across the 24-week study. That does not mean someone must wait four weeks for any response, or that every dose works immediately at minute 45. [2]

Early intranasal studies in men reported first erectile responses at approximately 30 minutes with the experimental nasal formulation. That finding belongs to those studies. It does not validate a 30-minute onset for the supplied spray, whose strength and formulation documents conflict. [4]

Cycle length: as-needed use and the eight-week check

PT-141 is not prescribed as a daily peptide cycle. The approved approach is as-needed administration with the spacing and monthly limits above. If HSDD symptoms have not improved after eight weeks, the label directs discontinuation. Eight weeks is a point to reassess benefit, not an instruction to keep administering despite side effects. [1]

Calendar duration and product quantity answer different questions. Four administrations at 1.75 mg total 7 mg. Eight total 14 mg. Those totals can help explain product amounts, but they do not establish how long a reconstituted research vial remains usable.

Ten divided by 1.75 gives approximately 5.71 mathematical portions: five complete 1.75 mg amounts would use 8.75 mg and leave 1.25 mg before losses. A fractional sixth portion is not a complete sixth administration. Preparation waste, storage instructions and a validated discard time remain separate considerations.

10 mg vial and PT-141 nasal spray

The vial contains 10 mg of freeze-dried PT-141 powder. It has a matching redacted certificate for lot PL-2609-080. Its concentration is determined only after preparation to a known final volume. The nasal format is already liquid, but its current strength cannot be confirmed from the conflicting materials. [6]

PRODUCT IMAGE

Freeze-dried peptide powder

PT-141 10 mg vial

10mg PT-141 per vial

10 mg of bremelanotide powder with the matching source report for lot PL-2609-080.

Contents

10 mg · 10,000 mcg

Form

Freeze-dried powder

Preparation

Mixing required

Sealed storage

−20°C (−4°F) · dry and dark

Redacted 10 mg vial COA

Powder lot PL-2609-080: 99.42% HPLC area purity. No separate mg-per-vial content assay.

View 10 mg vial

PRODUCT IMAGE

Ready-made nasal format

PT-141 nasal spray

—Strength needs confirmation

Ready-made spray. The written specifications and original bottle image show different strengths and preservatives.

Form

Prepared nasal solution

Per spray

Current calibration unconfirmed

Mixing

No powder to dissolve

Storage

2–8°C (36–46°F) · do not freeze

Written information says 10 mg with benzyl alcohol; the original images show 30 mg, 150 mcg per spray, saline and methylparaben. Current-lot strength and formulation need confirmation.

Batch COA pending.

View Nasal spray

Product photographs edited to remove supplier branding. Any unresolved specifications are identified on the product card.

The written nasal specifications describe 10 mg in water with 0.9% benzyl alcohol. The original images instead show 30 mg, 150 mcg per spray and 200 sprays, with saline and methylparaben on the side label. Those are different product descriptions. A current, batch-specific label and pump calibration are needed before calculating an amount per spray or comparing cost per milligram.

The product comparison shows the edited images and explains the discrepancy beside the spray. The vial certificate is attached to the powder product; it does not verify the finished spray's concentration, pump output or sterility.

PT-141 for men and combinations with ED medicines

Men have been included in early PT-141 research, including studies of erectile response. Investigators used controlled conditions and equipment to measure rigidity. Those findings provide evidence of a biological effect, but do not supply a reliable success percentage for men buying a vial or nasal spray online. [3]

Low desire and difficulty keeping an erection also need different assessment. PDE5 inhibitors such as sildenafil help erectile function through blood-flow mechanisms. Treatment may also need to address medication effects, low testosterone when present, or anxiety around sex. Changing a prescribed medicine or adding another drug without reviewing the cause can miss the problem that needs treatment. [8]

A small crossover study of 19 men examined intranasal PT-141 alongside sildenafil and found an enhanced measured erectile response. It was an exploratory combination study, not a validated routine stack for the supplied products. The study's nasal formulation, screening and monitoring matter, particularly because bremelanotide can raise blood pressure. [5]

The evidence is not a reason to assume that a larger amount, repeated administration on the same evening, or several sexual-function drugs together will produce a better experience. The approved frequency limit and cardiovascular restrictions still need attention; adding a drug with different blood-pressure effects does not make those effects cancel predictably.

PT-141 side effects

Nausea, flushing, injection-site reactions and headache were the most frequent adverse effects in the main injection trials. Nausea occurred in 40% of treated participants, flushing in 20.3%, injection-site reactions in 13.2% and headache in 11.3%. These are participant rates during the trials, not the probability attached to every injection. [1]

Nausea often begins within the first hour and commonly lasts around two hours. That timing can overlap the intended activity. Persistent or severe nausea is a reason to contact the prescriber about symptom management or discontinuation. The updated label reports that taking ondansetron in advance did not prevent it.

Bremelanotide can temporarily increase blood pressure and lower heart rate. Uncontrolled hypertension and known cardiovascular disease are contraindications. Darkened patches of skin or gums can also occur and may not completely disappear after stopping. The side-effects article covers symptom timing, medication interactions and when urgent assessment is needed.

Redacted PT-141 COA: lot PL-2609-080

The attached powder-lot report gives 99.42% HPLC area purity and a matching LC-MS identity result. It describes two sampled vials from a lot of 250 and includes water, endotoxin and sterility results. The redacted two-page PDF is available below. [7]

REDACTED COPY · IN-HOUSE REPORT

PT-141 10 mg — lot PL-2609-080

99.42% HPLC area purity

Label claim10 mg per powder vialLC-MS identity1025.4 DaEndotoxin0.04 EU/mgSterilityNo growth after 14 daysAnalysis date19 September 2026Sampled units2 of 250

2 sampled powder vials from lot PL-2609-080; in-house testing. No separate quantitative vial-fill assay or finished-spray testing.

Open redacted COA

Area purity describes the relative size of the peptide's chromatographic peak. It is not a separate measurement confirming exactly 10 mg in every vial. The certificate also does not establish an amount per spray, a safe reconstitution recipe, or the performance of a finished medicine.

Match the lot on a product to the lot on its report. The same ingredient name alone cannot extend this certificate to another batch or to a different finished format.